Published in Ann Am Thorac Soc on February 01, 2013
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J (2014) 2.28
Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med (2015) 1.73
Time to symptom resolution in young children treated for pulmonary tuberculosis. Pediatr Infect Dis J (2014) 0.92
Duration of Pulmonary Tuberculosis Infectiousness under Adequate Therapy, as Assessed Using Induced Sputum Samples. Tuberc Respir Dis (Seoul) (2016) 0.75
Dynamics of Cough Frequency in Adults Undergoing Treatment for Pulmonary Tuberculosis. Clin Infect Dis (2017) 0.75
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis (2011) 16.88
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med (2003) 14.40
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep (2010) 8.16
Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep (2005) 6.45
Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med (2011) 6.14
Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis. Lancet (2012) 5.81
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med (2010) 4.24
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
The effects of local review on informed consent documents from a multicenter clinical trials consortium. Control Clin Trials (2003) 3.30
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med (2009) 3.05
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93
Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis (2014) 2.75
Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis (2008) 2.69
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med (2003) 2.56
Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med (2008) 2.55
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis (2005) 2.34
Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis (2007) 2.28
Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med (2006) 2.23
Bacterial contamination of computer keyboards in a teaching hospital. Infect Control Hosp Epidemiol (2003) 2.21
Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med (2011) 2.17
Risk-based human immunodeficiency virus (HIV) testing fails to detect the majority of HIV-infected persons in medical care Settings. Sex Transm Dis (2006) 2.07
Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother (2002) 2.03
Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS (2008) 2.02
Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med (2004) 1.96
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS (2009) 1.95
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med (2009) 1.95
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med (2005) 1.85
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother (2007) 1.72
Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest (2003) 1.65
A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS (2004) 1.65
Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol (2007) 1.64
Antituberculosis drugs and hepatotoxicity. Respirology (2006) 1.62
Evaluation of a high-throughput repetitive-sequence-based PCR system for DNA fingerprinting of Mycobacterium tuberculosis and Mycobacterium avium complex strains. J Clin Microbiol (2004) 1.60
Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis (2010) 1.59
The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol (2009) 1.56
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis (2012) 1.53
Risk of active tuberculosis among schoolchildren in Hong Kong. Arch Pediatr Adolesc Med (2006) 1.52
Common roots: a contextual review of HIV epidemics in black men who have sex with men across the African diaspora. Lancet (2012) 1.48
Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med (2008) 1.47
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother (2010) 1.45
Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis (2003) 1.44
Seasonality of tuberculosis in the United States, 1993-2008. Clin Infect Dis (2012) 1.44
Widespread emergence of methicillin resistance in community-acquired Staphylococcus aureus infections in Denver. South Med J (2005) 1.44
Avoidable antibiotic exposure for uncomplicated skin and soft tissue infections in the ambulatory care setting. Am J Med (2013) 1.44
Lethal interaction: the colliding epidemics of tobacco and tuberculosis. Expert Rev Anti Infect Ther (2007) 1.41
A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis (2004) 1.39
Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One (2011) 1.38
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med (2011) 1.37
Seasonal pattern of tuberculosis in Hong Kong. Int J Epidemiol (2005) 1.35
Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin Diagn Lab Immunol (2002) 1.35
Tuberculosis in the global aging population. Infect Dis Clin North Am (2010) 1.34
Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy (2002) 1.31
Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer (2006) 1.28
Skin-test screening and tuberculosis transmission among the homeless. Emerg Infect Dis (2002) 1.28
Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J Virol (2002) 1.27
New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med (2010) 1.27
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother (2007) 1.26
Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother (2009) 1.24
Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One (2013) 1.24
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med (2002) 1.23
Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr (2003) 1.21
Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial. AIDS (2010) 1.20
Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am J Epidemiol (2006) 1.20
HIV impairs TNF-alpha mediated macrophage apoptotic response to Mycobacterium tuberculosis. J Immunol (2007) 1.19
Expanded geographical distribution of the N family of Mycobacterium tuberculosis strains within the United States. J Clin Microbiol (2004) 1.18
Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One (2010) 1.15
Treatment of tuberculosis and optimal dosing schedules. Thorax (2010) 1.13
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol (2010) 1.11
How much directly observed therapy is enough? Am J Respir Crit Care Med (2004) 1.10
Epidemiology of healthcare-associated bloodstream infection caused by USA300 strains of methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Infect Control Hosp Epidemiol (2009) 1.07
Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr (2005) 1.07
Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis. Emerg Infect Dis (2009) 1.05